Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLS-2031 in Neuropathic Pain from Lumbosacral Radiculopathy
NCT04238793Phase 2Completed
- Sponsor
- Kolon Life Science Inc.
- Start
- Apr 2020
- Primary completion
- Oct 2023
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KLS-2031 in neuropathic pain and lumbosacral radiculopathy (3 cohorts), sponsored by Kolon Life Science Inc. Primary endpoint: Safety and tolerability of KLS-2031 at Week 52. Started Apr 2020; status: completed.
02
Drugs
KLS-2031
03
Conditions
neuropathic painlumbosacral radiculopathy
Beyond the preview
Go deeper on NCT04238793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238793.